Hubei Biocause Heilen Pharmaceutical (301211.SZ): Fiposidone tablets obtained drug registration certificate.

15:56 21/10/2025

Hengdi Pharmaceutical (301211.SZ) announced that the company recently received the approval and issuance of the "Drug... by the National Medical Products Administration.

Hubei Biocause Heilen Pharmaceutical (301211.SZ) announced that the company recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for the drug Febuxostat. Febuxostat is a xanthine oxidase inhibitor used primarily for long-term treatment of hyperuricemia and gout patients (including uric acid-lowering treatment after acute attacks of gouty arthritis).

SHOUGANG CENT (00103) spent HKD 750,500 to repurchase 950,000 shares on October 21st.

SINOPHARM(01099): China National Medicines Corporation(600511.SH) net profit attributable to parent company for the first three quarters was 1.492 billion yuan, an increase of 0.74% year-on-year.

TIANGONG INT'L (00826) obtained a loan financing of HKD 78.2075 million from a licensed bank in Hong Kong.

SHOUGANG CENT (00103) spent HKD 750,500 to repurchase 950,000 shares on October 21st.

SINOPHARM(01099): China National Medicines Corporation(600511.SH) net profit attributable to parent company for the first three quarters was 1.492 billion yuan, an increase of 0.74% year-on-year.

TIANGONG INT'L (00826) obtained a loan financing of HKD 78.2075 million from a licensed bank in Hong Kong.